Holen Sie sich die Stockscreener-App
1.43
5.15%
0.07
Schlusskurs vom Vortag:
$1.36
Offen:
$1.37
24-Stunden-Volumen:
185.48K
Relative Volume:
0.17
Marktkapitalisierung:
$89.85M
Einnahmen:
$13.86M
Nettoeinkommen (Verlust:
$-79.62M
KGV:
-1.1141
EPS:
-1.2835
Netto-Cashflow:
$-63.51M
1W Leistung:
-6.54%
1M Leistung:
-5.92%
6M Leistung:
-30.58%
1J Leistung:
+24.35%
1-Tages-Spanne:
$1.36
$1.46
1-Wochen-Bereich:
$1.35
$1.575
52-Wochen-Spanne:
$0.8332
$5.55
Pyxis Oncology Inc Stock (PYXS) Company Profile
Firmenname
Pyxis Oncology Inc
Sektor
Branche
Telefon
(617) 221-9059
Adresse
321 HARRISON AVENUE, BOSTON
Compare PYXS vs VRTX, REGN, ALNY, ARGX, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PYXS
Pyxis Oncology Inc
|
1.43 | 85.45M | 13.86M | -79.62M | -63.51M | -1.2835 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Pyxis Oncology Inc Stock (PYXS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-03 | Fortgesetzt | Stifel | Buy |
| 2025-09-04 | Eingeleitet | Guggenheim | Buy |
| 2024-11-21 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2024-11-08 | Eingeleitet | Stephens | Overweight |
| 2024-08-08 | Eingeleitet | Stifel | Buy |
| 2024-05-07 | Fortgesetzt | Jefferies | Buy |
| 2024-02-09 | Eingeleitet | BTIG Research | Buy |
| 2024-01-23 | Eingeleitet | Leerink Partners | Outperform |
| 2023-09-05 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2021-11-02 | Eingeleitet | BofA Securities | Neutral |
| 2021-11-02 | Eingeleitet | Credit Suisse | Outperform |
| 2021-11-02 | Eingeleitet | Jefferies | Buy |
Alle ansehen
Pyxis Oncology Inc Aktie (PYXS) Neueste Nachrichten
Pyxis Oncology director Humphrey sells $15917 in shares By Investing.com - Investing.com Australia
Pyxis Oncology (PYXS) director receives 45,867 stock options at $1.36 strike - Stock Titan
Pyxis Oncology (PYXS) grants director Jakob Dupont 45,867 stock options - Stock Titan
Executive at Pyxis Oncology (PYXS) receives new option and RSU equity grants - Stock Titan
Pyxis Oncology director Humphrey sells $15917 in shares - Investing.com
Pyxis Oncology (PYXS) director receives grant of 45,867 stock options - Stock Titan
[Form 4] Pyxis Oncology, Inc. Insider T... - Stock Titan
Director at Pyxis Oncology (PYXS) receives grant of 45,867 stock options - Stock Titan
Pyxis Oncology (NASDAQ:PYXS) Director Rachel Humphrey Sells 13,896 Shares - MarketBeat
Pyxis Oncology (PYXS) director sells 15,496 shares under 10b5-1 plan - Stock Titan
FY2029 EPS Estimates for Pyxis Oncology Lifted by Analyst - MarketBeat
LifeSci Capital Maintains Pyxis Oncology(PYXS.US) With Buy Rating, Maintains Target Price $5 - Moomoo
A Quick Look at Today's Ratings for Pyxis Oncology(PYXS.US), With a Forecast Between $5 to $7 - Moomoo
Stifel Nicolaus Lowers Pyxis Oncology (NASDAQ:PYXS) Price Target to $8.00 - MarketBeat
Pyxis Oncology (NASDAQ:PYXS) Given Buy Rating at HC Wainwright - MarketBeat
Guggenheim reiterates Buy on Pyxis Oncology stock ahead of trial data By Investing.com - Investing.com South Africa
H.C. Wainwright reiterates Buy on Pyxis Oncology stock, $7 target - Investing.com
Pyxis Oncology (PYXS) Rating Reiterated as Buy by HC Wainwright & Co. | PYXS Stock News - GuruFocus
RBC Capital Initiates Pyxis Oncology(PYXS.US) With Buy Rating, Announces Target Price $5 - Moomoo
Stifel cuts Pyxis Oncology stock price target on financing assumptions - Investing.com
Pyxis Oncology Reports 2025 Financial Results, Advances MICVO Cancer Trials, and Announces New Leadership - Minichart
William Blair reiterates Pyxis Oncology stock rating on trial pace - Investing.com UK
Jefferies raises Pyxis Oncology stock price target on drug data By Investing.com - Investing.com Australia
Jefferies raises Pyxis Oncology stock price target on drug data - Investing.com
MicuRx Pharmaceuticals: Advancing Novel ADC Therapy MICVO for Difficult-to-Treat Head and Neck Cancer – Pipeline, Strategy, and Risks Overview - Minichart
Pyxis Oncology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Pyxis Oncology (NASDAQ:PYXS) Posts Earnings Results, Beats Expectations By $0.06 EPS - MarketBeat
Pyxis Oncology Reports Q4 Results, Advances MICVO Program - TipRanks
Pyxis Oncology 10-K: Revenue $13.9M; Net loss $(79.6)M - TradingView
Pyxis Oncology (PYXS) highlights MICVO ADC progress in head and neck cancer - Stock Titan
Pyxis Oncology (NASDAQ: PYXS) details 2025 results and MICVO head & neck cancer data - Stock Titan
Pyxis Oncology 2025 net loss widens on higher R&D spend - TradingView
BRIEF-Pyxis Oncology FY Net Income USD -79.621 Million - TradingView
Pyxis fills head and neck cancer study, says cash lasts into Q4 - Stock Titan
PYXS Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
PYXS Stock Price, Quote & Chart | PYXIS ONCOLOGY INC (NASDAQ:PYXS) - ChartMill
PYXS SEC FilingsPyxis Oncology, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Pyxis Oncology, Inc. (NASDAQ:PYXS) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Pyxis Oncology (NASDAQ:PYXS) Lowered to Sell Rating by Wall Street Zen - MarketBeat
Pyxis Oncology Inc expected to post a loss of 34 cents a shareEarnings Preview - TradingView
Pyxis Oncology (PYXS) Projected to Post Quarterly Earnings on Tuesday - MarketBeat
Pyxis Oncology (NASDAQ:PYXS) Stock Rating Upgraded by Wall Street Zen - Defense World
Pyxis Oncology (NASDAQ:PYXS) Upgraded at Wall Street Zen - MarketBeat
PYXS Technical Analysis & ETF Price Forecast - Intellectia AI
Will Pyxis Oncology Inc stock benefit from M A2025 Growth vs Value & Low Drawdown Momentum Trade Ideas - baoquankhu1.vn
PYXS Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Pyxis Oncology, Inc. (NASDAQ:PYXS) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Can Pyxis Oncology Inc. expand its profit marginsWeekly Trade Review & Low Drawdown Investment Ideas - mfd.ru
PYXS Should I Buy - Intellectia AI
Can Pyxis Oncology Inc. stock hit record highs againWeekly Risk Report & AI Powered Buy/Sell Recommendations - mfd.ru
Street Watch: Can Pyxis Oncology Inc sustain its profitabilityJuly 2025 News Drivers & Fast Gain Stock Tips - baoquankhu1.vn
Finanzdaten der Pyxis Oncology Inc-Aktie (PYXS)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):